Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
NASDAQ:QURE
Earnings Data
Report Date
Mar 02, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.91Last Year’s EPS
-1.49Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call showcased significant advancements in uniQure's therapeutic pipeline, particularly for Huntington's disease and epilepsy, despite regulatory challenges and increased operational costs. The financial position remains strong, supporting future operations. However, setbacks with the FDA's stance on AMT-130 and the pause in the AMT-162 program posed challenges.Company Guidance
Positive Top-Line Data for AMT-130 in Huntington's Disease
uniQure announced positive top-line data from their pivotal Phase 1/2 study of AMT-130, showing statistically significant 75% slowing of disease progression at three years compared to a control group. A 60% slowing was observed in a key secondary endpoint.
Financial Growth
uniQure's revenue for Q3 2025 was $3.7 million, up from $2.3 million in Q3 2024, marking an increase of $1.4 million. The increase was due to $1.5 million in license revenues.
Strong Cash Position
uniQure reported cash, cash equivalents, and investment securities totaling $649.2 million as of September 30, 2025, up from $376.5 million at the end of 2024, attributed to net proceeds from public offerings.
Encouraging Initial Data for AMT-260 in Epilepsy
Initial data from AMT-260 for mesial temporal lobe epilepsy showed a promising reduction in seizure frequency with no serious adverse events. Recruitment has expanded following a favorable review.
Fabry Disease Therapy Progress
Phase 1/2a trial of AMT-191 showed encouraging results, with one patient successfully withdrawing from enzyme replacement therapy while maintaining stable levels, indicating potential as a one-time gene therapy.
QURE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
QURE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 10, 2025 | $27.79 | $26.15 | -5.90% |
Jul 29, 2025 | $14.98 | $13.68 | -8.68% |
May 09, 2025 | $12.25 | $12.79 | +4.41% |
Feb 27, 2025 | $11.67 | $12.07 | +3.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does uniQure N.V. (QURE) report earnings?
uniQure N.V. (QURE) is schdueled to report earning on Mar 02, 2026, TBA (Confirmed).
What is uniQure N.V. (QURE) earnings time?
uniQure N.V. (QURE) earnings time is at Mar 02, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is QURE EPS forecast?
QURE EPS forecast for the fiscal quarter 2025 (Q4) is -0.91.